SGLT2 inhibitors vs GLP-1 receptor agonists for kidney outcomes in individuals with type 2 diabetes
JAMA Internal Medicine Peer-Reviewed Publication JAMA Network About The Study: This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in individuals with type 2 diabetes was associated with a lower 5-year risk of chronic kidney disease and a lower 5-year count of acute kidney injury. These […]
